Complement and Inflammation Inhibition drug products

ReAlta Life Sciences is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for rare and acute inflammatory diseases. Central to their approach is the EPICC platform, which utilizes a unique dual-targeting mechanism to modulate both the complement system and neutrophil-mediated inflammatory processes. This platform allows for rapid and dose-dependent inhibition of key components in the classical and lectin complement pathways, specifically targeting C1 and MBL. By addressing these critical pathways, ReAlta aims to rebalance the inflammatory response, potentially altering the progression of diseases driven by excessive inflammation.

The company's clinical pipeline includes several promising candidates, notably RLS-0071 (pegtarazimod), which has received Orphan Drug and Fast Track designations from the FDA for conditions such as hypoxic-ischemic encephalopathy (HIE) and acute graft-versus-host disease (aGvHD). ReAlta's research spans multiple therapeutic areas, including neurology, pulmonary, and hematology, with a focus on conditions like acute exacerbations of chronic obstructive pulmonary disease (COPD) and platelet refractoriness. By leveraging insights from the human astrovirus, which has evolved mechanisms to mitigate inflammation, ReAlta aims to provide new therapeutic options for patients suffering from these challenging diseases.

United States

ReAlta Life Sciences is a biotech company that focuses on rebalancing the inflammatory response to address life-threatening acute inflammatory and rare diseases with their EPICC peptides based on the human astrovirus research.

ReAlta Life Sciences

Company Details